A diazacyclobutene drug intermediate and its industrial synthesis method
By constructing activation intermediates using aziridine butylbenzothiazole sulfone as the backbone, and combining sulfone de-alkenoylation and direct deprotection salt formation methods, the problems of heat transfer, mass transfer, and purification pressure in the industrialization process of aziridine drug intermediates were solved, achieving more efficient backbone construction and purification continuity.
Patent Information
- Application Number
- CN202611369866.9
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2026-09-04
- Publication Date
- 2026-11-17
AI Technical Summary
Existing technologies for the industrialization of diazacyclobutene drug intermediates have difficulty controlling heat transfer, mass transfer, dropping, and purification pressure on a large scale, and rely on ultra-low temperatures and highly active reagents, leading to a concentration of problems in the process chain.
A nitrogen-containing heterocyclic butylbenzothiazole sulfone was used as the backbone to construct an activation intermediate. Carbon-carbon double bonds were formed through a desulfonation olefination reaction. The crude product after backbone construction was then directly introduced into the deprotection salt formation and crystallization separation stage, forming a continuous process path.
It reduces reliance on cryogenic control and highly active reagents, improves the controllability of the core framework construction process and the continuity of industrial operation, reduces deep purification steps, and is suitable for kilogram-scale production.
Smart Images

Figure CN123106499A_ABST
Abstract
Description
Technical Field
[0001] This invention relates to the field of organic compound preparation technology, specifically to a method for synthesizing nitrogen-containing strained heterocyclic drug intermediates, and more particularly to a diazacyclic butene drug intermediate and its industrial synthesis method. Background Technology
[0002] Diazacyclobutene drug intermediates contain strained heterocyclic skeletons formed by azacyclobutane structural units, exhibiting spatial conformations and electronic structures different from ordinary chain amine compounds. After removing protecting groups, these intermediates can form a diamine structure with two reactive amino groups. These two amino groups can participate in condensation, substitution, or reductive amination reactions, connecting different functional structural units, thus serving as core building blocks or active fragments for nitrogen-containing heterocyclic drug candidates. With the increasing structural types of nitrogen-containing heterocyclic candidate compounds and the advancement of drug development from laboratory screening to process development, pilot-scale verification, and large-scale preparation, higher demands are placed on the stable supply of these intermediates. Synthetic routes not only need to obtain the target compound under small-scale conditions but also need to meet requirements such as available raw materials, controllable reaction processes, reproducible batch results, and industrially feasible post-processing.
[0003] However, the diazacyclic butene skeleton involves crucial bonding between two ring-strained nitrogen heterocyclic structural units, and the skeleton construction process is highly sensitive to reactant activity, feeding sequence, local concentration, and reaction temperature. In small-scale laboratory preparations, the reaction can be controlled using ultra-low temperature conditions, highly reactive reagents, slow addition, and column chromatography purification. However, as the scale of materials increases, the heat and mass transfer states of the reaction system change accordingly. Differences in temperature, concentration, and mixing may occur at different locations within the reactor, making it easier to scale up processes that were previously controllable under small-scale conditions, such as localized over-reactions, instantaneous exothermic reactions, side reactions, and quenching processes. Therefore, the industrialization challenge of this type of intermediate is not limited to insufficient yield at a single reaction step, but rather lies in the fact that the bonding pattern of the core skeleton propagates upstream to reagent selection and reaction conditions, and downstream to intermediate separation, impurity removal, and target product purification, forming interconnected process constraints.
[0004] Chinese invention patent application CN118930525A discloses a method for preparing a diazapyridine-based Menin-MLL protein inhibitor and its related intermediates. The method employs an ultra-low temperature organolithium reaction system to prepare the related diazapyridine skeletal intermediates. The reaction process involves multiple temperature changes and controlled dropwise additions. Subsequent steps utilize reagents such as methanesulfonyl chloride, and separation is achieved at several intermediate stages using column chromatography or preparative liquid chromatography. While this route enables the laboratory preparation of the target structure, its key bonding depends on ultra-low temperatures and highly reactive reagents, and multiple intermediate stages require separate purification. This places significant pressure on the route in terms of equipment cooling capacity, feed safety, process control, solvent consumption, and batch post-processing.
[0005] This demonstrates that, on the one hand, drug development and pilot-scale production create a stable and scalable external demand for diazacyclic butene intermediates; on the other hand, the strained heterocyclic structure of these compounds inherently relies on strong reaction-driving forces and a narrow reaction control window for core framework construction. The interaction between external scaling demands and the bonding characteristics of the internal framework causes existing laboratory-scale problems such as cryogenic control, the use of highly reactive reagents, complex quenching, and multi-step separation to become prominent during scale-up. These problems are not solely caused by operator or equipment conditions, but rather represent a chain-wide issue stemming from existing framework construction methods, reagent systems, and post-processing techniques.
[0006] The technical problem to be solved by this invention is: how to establish a controllable core skeleton bonding mechanism in a target molecule containing a high-strength nitrogen heterocyclic unit, so that it can reliably form a diaza-heterocyclic butene skeleton and withstand the heat transfer, mass transfer, dropping, quenching and purification pressure brought about by kilogram-scale scale-up. Summary of the Invention
[0007] To address the aforementioned technical problems, this invention provides an industrial synthesis method for diazacyclobutene drug intermediates. This method uses diazacyclobutane benzothiazole sulfone as the backbone of an activated intermediate. Through desulfonation and olefination, a central carbon-carbon double bond is formed between two diazacyclobutane structural units. The crude product after backbone construction directly enters the deprotection, salt formation, and crystallization separation stages, thus establishing a continuous process relationship between the core bonding pathway and the industrial post-processing pathway.
[0008] An industrial synthesis method for a diazacyclobutene drug intermediate includes the following steps: adding 3-benzothiazol-2-sulfonyl diazacyclobutane-1-carboxylate tert-butyl ester and 3-oxozycyclobutane-1-carboxylate benzyl ester to a mixed solvent composed of tetrahydrofuran and N,N-dimethylformamide; controlling the temperature of the reaction system to 0 to 5 degrees Celsius under an inert atmosphere; adding hexamethyldisilamide lithium dropwise to the reaction system and reacting it to allow the 3-benzothiazol-2-sulfonyl diazacyclobutane-1-carboxylate tert-butyl ester and the 3-oxozycyclobutane-1-carboxylate benzyl ester to undergo a desulfonyl olefination reaction, forming a carbon-carbon double bond between two diazacyclobutane structural units, to obtain a crude diazacyclobutene skeleton intermediate with double protection.
[0009] The crude bis(azirocyclobutene) skeleton intermediate obtained was directly dissolved in ethyl acetate without column chromatography purification. P-Toluenesulfonic acid was added to react with the intermediate, removing the tert-butoxycarbonyl protecting group and causing the resulting amino group to form a salt with p-toluenesulfonic acid. After the reaction was complete, the reaction system was cooled, causing the p-toluenesulfonate salt of the bis(azirocyclobutene) drug intermediate to precipitate. Solid-liquid separation was then performed by filtration or centrifugation to obtain the target product.
[0010] This invention does not isolate the framework construction reaction and the deprotection reaction. Instead, it allows the crude product formed after framework construction to directly enter the deprotection and salt formation stage. By utilizing the solubility difference between the target salt form and the benzothiazole-related components, the target product is separated during the salt formation and crystallization process, thus forming a continuous process path between the core bonding process and the subsequent industrial purification process.
[0011] As a further technical solution, the inert atmosphere is a nitrogen atmosphere.
[0012] As a further technical solution, the 3-benzothiazol-2-sulfonylaziridine-1-carboxylic acid tert-butyl ester is prepared according to the following steps: 3-iodoaziridine-1-carboxylic acid tert-butyl ester and benzothiazol-2-thiol are added to the reaction system, and a thioetherification reaction is carried out under alkaline conditions to obtain 3-benzothiazol-2-ylthioaziridine-1-carboxylic acid tert-butyl ester; 3-benzothiazol-2-ylthioaziridine-1-carboxylic acid tert-butyl ester is dissolved in methanol, and hydrogen peroxide is added under the presence of sodium tungstate to carry out an oxidation reaction, so that the benzothiazolium thio group fragment is converted into the benzothiazolium sulfonyl group fragment to obtain 3-benzothiazol-2-sulfonylaziridine-1-carboxylic acid tert-butyl ester.
[0013] Through the above-mentioned thioetherification and oxidation processes, commercially available azacyclobutane feedstock is converted into a sulfone-activated intermediate that can participate in the desulfonation olefination reaction under alkaline conditions. This sulfone-activated intermediate simultaneously undertakes the functions of introducing azacyclobutane structural units, carbon-carbon bonding, and the departure of benzothiazole sulfone fragments.
[0014] As a further technical solution, the alkali used in the thioetherification reaction is potassium carbonate, the reaction solvent is N,N-dimethylformamide, the reaction temperature is 80 degrees Celsius, and the reaction time is 2 hours.
[0015] As a further technical solution, after the thioetherification reaction is completed, ethyl acetate and water are added to the reaction system for extraction. The aqueous phase is further extracted with ethyl acetate. The resulting organic phases are combined, washed and concentrated with sodium chloride aqueous solution to obtain tert-butyl 3-benzothiazol-2-ylthioazine-1-carboxylic acid.
[0016] As a further technical solution, the oxidation reaction temperature is 20 to 25 degrees Celsius, the amount of hydrogen peroxide is 2 to 3 equivalents relative to tert-butyl 3-benzothiazol-2-ylthioazonicyclobutane-1-carboxylic acid, and the oxidation reaction time is 3 to 5 hours.
[0017] As a further technical solution, after the oxidation reaction is completed, the temperature of the reaction system is controlled at 10 to 15 degrees Celsius, and an aqueous solution of sodium thiosulfate is added to the reaction system to quench the residual peroxides in the reaction system. After quenching, solid-liquid separation and drying are performed to obtain solid tert-butyl 3-benzothiazolium-2-sulfonylazine-1-carboxylic acid.
[0018] As a further technical solution, during the desulfonation olefination reaction, tert-butyl 3-benzothiazolium-2-sulfonylazacyclobutane-1-carboxylate and benzyl 3-oxozazenecyclobutane-1-carboxylate are added to a mixed solvent of tetrahydrofuran and N,N-dimethylformamide, the reaction system is purged with nitrogen, and then the reaction system is cooled to 0 to 5 degrees Celsius.
[0019] As a further technical solution, the hexamethyldisilamide lithium is added dropwise in the form of a solution with a concentration of 1 mol / L. During the dropwise addition, the temperature of the reaction system is controlled at 0 to 5 degrees Celsius, the dropwise addition time is 2 to 4 hours, and the reaction continues at 0 degrees Celsius for 2 hours after the dropwise addition is completed.
[0020] As a further technical solution, after the desulfonation olefin reaction is completed, the temperature of the reaction system is controlled at 0 to 10 degrees Celsius, and an aqueous solution of ammonium chloride is added dropwise to the reaction system for quenching. After quenching, the mixture is allowed to stand and separate into layers. The aqueous phase is extracted with ethyl acetate, and the resulting organic phases are combined. Then, the mixture is washed, dried, and concentrated with an aqueous solution of sodium chloride to obtain a crude intermediate of a double-protected diazacyclobutene skeleton.
[0021] As a further technical solution, the benzothiazole-related components remaining in the crude intermediate of the double-protected diazacyclobutene skeleton are not separated by independent column chromatography, and the crude product obtained is directly used for subsequent deprotection and salt formation reactions.
[0022] As a further technical solution, during the deprotection and salt formation reaction, the crude bis-protected diazacyclobutene skeleton intermediate is dissolved in ethyl acetate, p-toluenesulfonic acid is added, and the reaction is carried out at 50 to 55 degrees Celsius for 12 hours. The amount of p-toluenesulfonic acid relative to the bis-protected diazacyclobutene skeleton intermediate is 2 to 4 equivalents.
[0023] As a further technical solution, after the deprotection and salt formation reaction is completed, the reaction system is cooled to 20 to 25 degrees Celsius and stirred for 2 hours to precipitate the p-toluene sulfonate of the diazacyclobutene drug intermediate from ethyl acetate, and then separated by filtration or centrifugation.
[0024] As a further technical solution, column chromatography purification is not performed from the formation of the double-protected diazacyclobutene skeleton intermediate to the separation of the p-toluene sulfonate of the diazacyclobutene drug intermediate.
[0025] This invention also provides a sulfone-activated intermediate for preparing diazacyclobutene drug intermediates, wherein the sulfone-activated intermediate is tert-butyl 3-benzothiazolium-2-sulfonylazirhexacyclobutane-1-carboxylate. The sulfone-activated intermediate is prepared from tert-butyl 3-benzothiazolium-2-ylthioazirhexacyclobutane-1-carboxylate via sodium tungstate and hydrogen peroxide, and is used to undergo a desulfonation olefination reaction with benzyl 3-oxozyrhexacyclobutane-1-carboxylate to construct a diazacyclobutene skeleton.
[0026] Beneficial effects Compared with the prior art, the present invention has the following beneficial effects: Firstly, this invention uses aza-heterocyclic butylbenzothiazole sulfone as the activated intermediate for framework construction, and then, under the action of hexamethyldisilamide lithium, the sulfone activated intermediate undergoes a desulfonation olefination reaction with 3-oxozyracyclobutane-1-carboxylic acid benzyl ester, thus changing the reaction pathway for constructing the related diaza-heterocyclic framework dependent on ultra-low temperature organolithium systems. The core bonding reaction can be carried out under controlled conditions of 0 to 5 degrees Celsius, which helps to reduce the process pressure on kilogram-scale scale-up caused by ultra-low temperature control, multiple temperature transitions, and local excess of highly reactive reagents, and improves the controllability of the core framework construction process.
[0027] Secondly, this invention uses commercially available azacyclobutane raw material and benzothiazole-2-thiol to prepare sulfone activation intermediates, and uses a hydrogen peroxide and sodium tungstate system to complete the thioether oxidation. This allows the upstream activation intermediates to be obtained through operations such as thioetherification, oxidation, quenching, centrifugation and drying, reducing dependence on reagent systems with higher prices, stronger reactivity or higher toxicity in the original route. This makes the preparation method of the framework construction precursor more suitable for integration with conventional industrial equipment.
[0028] Third, this invention allows the crude product obtained from skeleton construction to be directly used in the deprotection and salt formation reaction, and completes the removal of the tert-butyloxycarbonyl protecting group, the formation of p-toluenesulfonate, and the crystallization of the target product in the same process stage, so that the benzothiazole-related components in the crude product can be removed in the subsequent crystallization process. This reduces the independent deep purification steps of the skeleton intermediates, and allows the entire route to be completed mainly through conventional operations such as extraction, washing, quenching, concentration, centrifugation, drying, and crystallization, improving the continuity and convenience of industrial operation. Attached Figure Description
[0029] Figure 1 This is a flowchart illustrating the overall industrial synthesis process of this invention. Figure 2 This is a chemical transformation route diagram between the starting materials, intermediates and target products of this invention; Figure 3 The bonding logic diagram for the sulfone-activated intermediate of the present invention participating in desulfonation olefination and forming a diazacyclobutene core framework; Figure 4 This is a process coupling diagram of the direct transfer of the crude skeleton product, deprotection and salt formation, and crystallization and impurity removal in this invention.
[0030] Figure reference numerals: 101—thioetherification step, 102—oxidation to sulfone step, 103—desulfonation olefination step, 104—deprotection salt formation and crystallization step, SM1—3-iodozacyclobutane-1-carboxylic acid tert-butyl ester, SM2—benzothiazol-2-thiol, SM3—3-oxozacyclobutane-1-carboxylic acid benzyl ester. Detailed Implementation
[0031] To make the objectives, technical solutions, and advantages of this invention clearer, the invention will be further described in detail below with reference to the accompanying drawings and embodiments. It should be understood that the specific embodiments described herein are for illustrative purposes only and are not intended to limit the invention.
[0032] In the following examples, SM1 is tert-butyl 3-iodozacyclobutane-1-carboxylate, SM2 is benzothiazol-2-thiol, and SM3 is benzyl 3-oxozyzacyclobutane-1-carboxylate. Compound 1 is a thioether intermediate formed by the thioetherification reaction of SM1 and SM2; Compound 2 is a sulfone-activated intermediate formed by the oxidation of Compound 1; Compound 3 is a double-protected bis(oxo)cyclobutene skeleton intermediate formed by the reaction of Compound 2 and SM3; and Compound 4 is p-toluenesulfonate formed by removing the tert-butyloxycarbonyl protecting group from Compound 3.
[0033] Lithium hexamethyldisilamide (LiHMDS) is used in the reaction. The following reaction can be carried out in a reaction vessel equipped with stirring, temperature control, material dropwise addition, and inert gas purging. The reaction process is monitored using high-performance liquid chromatography (HPLC) at a detection wavelength of 214 nm.
[0034] Example 1 This example illustrates the preparation of thioether intermediate compound 1.
[0035] Add 18 kg of SM1 and 176 kg of N,N-dimethylformamide to the reaction vessel, and start stirring to dissolve SM1. Add 13.8 kg of SM2 and then 14.1 kg of potassium carbonate to the reaction system. After the addition is complete, heat the reaction system to 80 degrees Celsius and stir the reaction at this temperature for two hours.
[0036] The remaining amount of SM1 was monitored using high-performance liquid chromatography (HPLC) during the reaction. Heating was stopped once the reaction of SM1 was confirmed to be complete. Ethyl acetate and water were added to the reaction system, and the mixture was stirred thoroughly and allowed to stand for phase separation. The organic phase was separated and extracted twice with ethyl acetate against the aqueous phase. The organic phases obtained from each extraction were combined and washed three times with a saturated sodium chloride aqueous solution.
[0037] After washing, the organic phase was concentrated to obtain 20.5 kg of crude oily compound 1. According to the original production records, the recorded yield of compound 1 was 100%, and the purity was 98% when measured using 214 nm.
[0038] In this embodiment, potassium carbonate promotes the thioetherification reaction between SM1 and SM2, allowing the benzothiazole thio group fragment to be incorporated into the azacyclic butane structure, providing a structural basis for the subsequent conversion of the thioether into a sulfone activated intermediate. Compound 1 obtained was not purified by column chromatography and was directly used in the oxidation reaction of Example 2.
[0039] Example 2 This example illustrates the preparation of sulfone-activated intermediate compound 2.
[0040] Twenty-five kilograms of the crude compound 1 obtained in Example 1 were added to a reaction vessel, followed by eighty-two kilograms of methanol. The mixture was stirred to disperse or dissolve compound 1. Three and a half kilograms of sodium tungstate were then added to the reaction system. The temperature of the reaction system was controlled at twenty to twenty-five degrees Celsius, and eighteen kilograms of hydrogen peroxide with a mass fraction of 30% was slowly added dropwise. During the dropwise addition, the temperature of the reaction system was maintained within the above range by adjusting the dropwise addition rate and the cooling intensity.
[0041] After the hydrogen peroxide was added dropwise, the reaction was continued to be stirred at room temperature for three hours. The remaining amount of compound 1 was monitored by high performance liquid chromatography to confirm that the reaction of compound 1 was complete.
[0042] The reaction system was cooled to 10-15 degrees Celsius, and sodium thiosulfate aqueous solution was added dropwise within this temperature range to quench any residual peroxides in the reaction system. After the addition was complete, stirring was continued at 10-15 degrees Celsius for 60 minutes.
[0043] After stirring, the mixture was centrifuged, and the resulting solid was collected. The solid was dried at 70 degrees Celsius to obtain 22.7 kg of white solid compound 2. According to the original production records, the recorded yield of compound 2 was 100%, and the purity was 92% when measured using 214 nm.
[0044] In this embodiment, sodium tungstate and hydrogen peroxide oxidize the sulfide structure in compound 1 to a sulfone structure, thereby forming a sulfone-activating unit in the resulting compound 2 that can participate in subsequent skeleton construction reactions. The resulting compound 2 can be centrifuged and dried in solid form, which is beneficial for weighing, transferring, and subsequent batch feeding, and can be directly used in Example 3.
[0045] Example 3 This embodiment illustrates the preparation of the dual-protected backbone intermediate compound 3.
[0046] Twenty-two and seven-tenths kilograms of compound 2 obtained in Example 2 and seventeen kilograms of SM3 were added to the reaction vessel, followed by one hundred and sixty-one kilograms of tetrahydrofuran and forty-three kilograms of N,N-dimethylformamide, and stirring was started.
[0047] The reaction vessel was purged with nitrogen three times. After purging, the reaction system was cooled to 0-5 degrees Celsius. While maintaining the reaction system temperature at 0-5 degrees Celsius, 95.34 kg of a 1 mol / L LiHMDS solution was added dropwise to the reaction system. The dropping rate was controlled according to the heat exchange capacity of the reaction system to ensure that the temperature of the reaction system did not exceed 5 degrees Celsius during the dropping process.
[0048] After the LiHMDS was added dropwise, the reaction system was maintained at 0 degrees Celsius and the reaction was continued with stirring for two hours. The reaction of compounds 2 and SM3 was monitored using high-performance liquid chromatography.
[0049] After the reaction was complete, the temperature of the reaction system was controlled between 0 and 10 degrees Celsius, and a saturated ammonium chloride aqueous solution was slowly added dropwise for quenching. During the addition, the temperature of the reaction system was controlled not to exceed 10 degrees Celsius. After quenching, the mixture was allowed to stand and separate into layers. The organic phase was separated and extracted twice with ethyl acetate. The organic phases obtained from each extraction were combined and then washed three times with a saturated sodium chloride aqueous solution.
[0050] After washing, the organic phase was dried with anhydrous sodium sulfate. The desiccant was filtered off and the organic phase was concentrated to obtain 340 kg of crude oily compound.
[0051] In this embodiment, compound 2, as a sulfone-activated intermediate, undergoes a desulfonation olefination reaction with SM3 under the action of LiHMDS, forming a carbon-carbon double bond between two aziridine structural units, thereby constructing a diaziridine skeleton. The resulting crude compound 3 contains benzothiazole-related components. These components do not interfere with the subsequent deprotection and salt formation reaction; therefore, compound 3 is not purified by column chromatography, and the resulting crude product is directly used in Example 4.
[0052] Example 4 This embodiment illustrates the preparation of target p-toluenesulfonate compound 4.
[0053] The crude compound 3 obtained in Example 3 was converted to the theoretical amount of 22 kg and added to the reaction vessel. 175.5 kg of ethyl acetate was added to the reaction vessel, and stirring was started to disperse or dissolve the crude compound 3. Then, 22 kg of p-toluenesulfonic acid was added.
[0054] The reaction system was heated to 50-55 degrees Celsius and stirred within this temperature range for 12 hours. The conversion of compound 3 was monitored using high-performance liquid chromatography (HPLC) during the reaction. Under the action of p-toluenesulfonic acid, the tert-butyloxycarbonyl protecting group in compound 3 was removed, and the resulting amino group formed a salt with p-toluenesulfonic acid. The free amine intermediate was not separated during this process.
[0055] After the reaction was complete, the reaction system was cooled to 20-25 degrees Celsius and stirred for another two hours within this temperature range to allow the target p-toluenesulfonate to precipitate from the ethyl acetate system. After stirring, centrifugation was performed, and the white solid was collected to obtain 14.5 kg of target compound 4. According to the original production records, the yield of compound 4 was 55%, and the purity was 98% when detected using 214 nm.
[0056] This embodiment integrates the removal of the tert-butyloxycarbonyl protecting group, the formation of p-toluenesulfonate, and the crystallization of the target product into the same reaction stage. In Example 3, the benzothiazole-related components in the crude product can be removed during salt formation crystallization and solid-liquid separation, thus avoiding the need for a separate column chromatography purification step in Compound 3.
[0057] Example 5 This embodiment illustrates the process relationship of continuous implementation of the entire process and direct transfer of crude product in this invention.
[0058] The industrial synthesis method of the present invention was carried out sequentially according to Examples 1 to 4. First, starting with SM1 and SM2, compound 1 was obtained by a potassium carbonate-promoted thioetherification reaction. After extraction, washing, and concentration, compound 1 was directly introduced into an oxidation system composed of sodium tungstate and hydrogen peroxide without column chromatography purification.
[0059] Next, the obtained compound 1 was oxidized to a solid sulfone-activated intermediate compound 2. Compound 2 was quenched with sodium thiosulfate, centrifuged, and dried before being used in a skeleton-building reaction with SM3.
[0060] Subsequently, LiHMDS was added dropwise under a nitrogen atmosphere and at 0 to 5 degrees Celsius to induce a desulfonation olefination reaction between compound 2 and SM3, yielding compound 3, a biprotected diazacyclobutene skeleton intermediate. Compound 3 was quenched with ammonium chloride, extracted with ethyl acetate, washed with sodium chloride aqueous solution, dried and concentrated with anhydrous sodium sulfate, and then directly proceeded to the deprotection and salt formation stage of p-toluenesulfonic acid without column chromatography purification.
[0061] Finally, the crude compound 3 was treated with p-toluenesulfonic acid in ethyl acetate to complete deprotection and salt formation in the same stage, and then compound 4 was obtained by cooling crystallization and centrifugation.
[0062] In this continuous production process, the sulfidation stage yielded 20.5 kg of crude compound 1 with a purity of 98% when detected using 214 nm; the oxidation stage yielded 22.7 kg of compound 2 with a purity of 92% when detected using 214 nm; the framework construction stage yielded 40 kg of crude compound 3; and the deprotection and salt formation stage yielded 14.5 kg of compound 4 with a purity of 98% when detected using 214 nm.
[0063] This embodiment demonstrates that the material processing from the infeed of commercially available azacyclobutane feedstock to the separation of the target p-toluenesulfonate can be completed sequentially using extraction, washing, concentration, quenching, centrifugation, drying, and crystallization. In particular, the crude compound 3 obtained from framework construction can directly enter the deprotection and salt formation stage without column chromatography, ultimately yielding the target solid with a purity of 98%. This establishes a continuous process relationship between core framework construction and final crystallization purification.
[0064] The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. Any modifications, equivalent substitutions and improvements made within the spirit and principles of the present invention should be included within the protection scope of the present invention.
Claims
1. An industrial synthesis method for a diazacyclobutene drug intermediate, characterized in that, Includes the following steps: 3-Benzothiazole-2-sulfonylazacyclobutane-1-carboxylic acid tert-butyl ester and 3-oxozycyclobutane-1-carboxylic acid benzyl ester were added to a mixed solvent composed of tetrahydrofuran and N,N-dimethylformamide. The temperature of the reaction system was controlled at 0 to 5 degrees Celsius under an inert atmosphere. Hexamethyldisilamide lithium was added dropwise to the reaction system and the reaction was carried out, causing the 3-benzothiazole-2-sulfonylazacyclobutane-1-carboxylic acid tert-butyl ester and the 3-oxozycyclobutane-1-carboxylic acid benzyl ester to undergo a desulfonyl olefination reaction to obtain a crude intermediate of a double-protected bisazacyclobutene skeleton. The crude bis(azirocyclobutene) skeleton intermediate was dissolved directly in ethyl acetate without column chromatography purification. P-Toluenesulfonic acid was added to react with the crude intermediate, thereby removing the tert-butoxycarbonyl protecting group from the bis(azirocyclobutene) skeleton intermediate. The amino group formed after deprotection formed a salt with p-toluenesulfonic acid. The mixture was then cooled to crystallize and separated into solid and liquid phases to obtain the p-toluenesulfonate salt of the bis(azirocyclobutene) drug intermediate.
2. The industrial synthesis method according to claim 1, characterized in that, The 3-benzothiazole-2-sulfonylazonylbutane-1-carboxylic acid tert-butyl ester was prepared according to the following method: 3-Iodozacyclobutane-1-carboxylic acid tert-butyl ester was reacted with benzothiazol-2-thiol under alkaline conditions to give 3-benzothiazol-2-ylthiozacyclobutane-1-carboxylic acid tert-butyl ester. The 3-benzothiazol-2-ylthioazonicyclobutane-1-carboxylic acid tert-butyl ester was dissolved in methanol, and hydrogen peroxide was added in the presence of sodium tungstate to carry out an oxidation reaction to obtain the 3-benzothiazol-2-sulfonylazonicyclobutane-1-carboxylic acid tert-butyl ester.
3. The industrial synthesis method according to claim 2, characterized in that, The thioetherification reaction uses potassium carbonate as the base, N,N-dimethylformamide as the reaction solvent, at a temperature of 80 degrees Celsius, and for a reaction time of 2 hours.
4. The industrial synthesis method according to claim 2, characterized in that, The oxidation reaction is carried out at a temperature of 20 to 25 degrees Celsius, and the amount of hydrogen peroxide is 2 to 3 equivalents relative to tert-butyl 3-benzothiazol-2-ylthioazacyclobutane-1-carboxylic acid. The reaction time is 3 to 5 hours. After the oxidation reaction is completed, the temperature of the reaction system is controlled at 10 to 15 degrees Celsius, and sodium thiosulfate aqueous solution is added to quench the residual peroxide.
5. The industrial synthesis method according to claim 1, characterized in that, The hexamethyldisilamide lithium was added dropwise as a solution with a concentration of 1 mol / L. During the dropwise addition, the temperature of the reaction system was controlled at 0 to 5 degrees Celsius, and the dropwise addition time was 2 to 4 hours. After the dropwise addition was completed, the reaction was carried out at 0 degrees Celsius for 2 hours.
6. The industrial synthesis method according to claim 1 or 5, characterized in that, After the desulfonation olefination reaction is completed, the temperature of the reaction system is controlled at 0 to 10 degrees Celsius and ammonium chloride aqueous solution is added dropwise for quenching. After standing and separating into layers, the aqueous phase is extracted with ethyl acetate. The obtained organic phases are combined and washed, dried and concentrated in sodium chloride aqueous solution to obtain the crude product of the double-protected diazacyclobutene skeleton intermediate.
7. The industrial synthesis method according to claim 1, characterized in that, The amount of p-toluenesulfonic acid relative to the biprotected diazacyclobutene skeleton intermediate is 2 to 4 equivalents, the deprotection salt formation reaction temperature is 50 to 55 degrees Celsius, and the reaction time is 12 hours.
8. The industrial synthesis method according to any one of claims 1 to 7, characterized in that, After the deprotection and salt formation reaction is completed, the reaction system is cooled to 20 to 25 degrees Celsius and stirred for 2 hours to precipitate the p-toluene sulfonate of the diazacyclobutene drug intermediate from ethyl acetate. The solid-liquid separation is then performed by filtration or centrifugation. No column chromatography purification is performed from the formation of the diazacyclobutene skeleton intermediate until the separation of the p-toluene sulfonate.
9. A sulfone-activated intermediate for preparing diazacyclic butene drug intermediates, characterized in that, The sulfone activation intermediate is tert-butyl 3-benzothiazole-2-sulfonylazine-1-carboxylic acid.
Citation Information
Patent Citations
Azacycloalkane Menin-MLL protein inhibitor as well as pharmaceutical composition and application thereof
CN118930525A
